Transwell invasion assay indicated that miR-718 inhibitors increased MCF-7 cells invasion ability, and miR-718 inhibitors could abolish the effects of FBXL19-AS1 knockdown on BC cells (Figure 4C; P<0.05). Here, FBXL19 is linked to breast cancer.